Focus on stem cell-based therapy for retinal degenerative diseases
10.3760/cma.j.issn.2095-0160.2019.11.001
- VernacularTitle: 关注视网膜退行性疾病干细胞治疗研究
- Author:
Qinghuai LIU
1
Author Information
1. Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
- Publication Type:Editorial
- Keywords:
Retinal degenerative diseases;
Stem cell;
Photoreceptor;
Retinal pigment epithelium;
Cell replacement therapy
- From:
Chinese Journal of Experimental Ophthalmology
2019;37(11):849-853
- CountryChina
- Language:Chinese
-
Abstract:
Retinal degenerative diseases are the common cause of blindness for all ages.Cell replacement therapy is the main strategy for treating retinal degenerative diseases.Recently, several retinal pigment epithelium(RPE) transplantation clinical trials have taken place worldwide and greatly enhanced the visual function of patients.However, irreversible loss of photoreceptors has been found in the late stage of diseases.Thus, photoreceptor transplantation is essential for the treatment of late-stage retinal degenerative diseases.How to obtain the clinical-grade amount of human cone photoreceptors remains to be one of the technical obstacles.This review introduced the present clinical trials of RPE transplantation and research achievements of photoreceptor transplantation.Furthermore, we will focus on the studies of stem cell-derived human photoreceptor differentiation.Lastly, the difficulties and future directions of stem cell-based therapy for retinal degenerative diseases will be discussed.
